Trials / Completed
CompletedNCT04810182
Regorafenib in Patients With Relapsed Glioblastoma. IOV-GB-1-2020 REGOMA-OSS
Regorafenib in Relapsed Glioblastoma. An Observational, Multicentric and Prospective Study. IOV-GB-1-2020 REGOMA-OSS
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 192 (actual)
- Sponsor
- Istituto Oncologico Veneto IRCCS · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to analyze the role the of Regorafenib in prolonging the Overall Survival of glioblastoma multiforme patients who progressed after surgery and a first-line chemo-radiotherapy treatment in the setting of "real world life".
Detailed description
The primary aim of the study
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Regorafenib 40 MG Oral Tablet [STIVARGA] | As per the treating physicians discretion |
Timeline
- Start date
- 2020-09-10
- Primary completion
- 2023-12-31
- Completion
- 2023-12-31
- First posted
- 2021-03-22
- Last updated
- 2024-02-08
Locations
29 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT04810182. Inclusion in this directory is not an endorsement.